Theragene Pharmaceuticals, Inc.

Theragene Pharmaceuticals, Inc. is a biotechnology firm focused on developing advanced immunotherapy and gene therapy solutions aimed at treating cancer and cardiovascular diseases. Founded in 2011 and headquartered in San Diego, California, Theragene Pharmaceuticals specializes in immunotherapy and gene therapy. The company has engaged in three funding deals, with the most recent being a Seed round in December 2017 that raised USD 0.

20 mn from Thynk Capital. It has no known parent or subsidiary companies. Theragene Pharmaceuticals specializes in advanced immunotherapy and gene therapy solutions, primarily targeting cancer and cardiovascular diseases. The company's core offerings include immunotherapy technologies that enhance the immune system's capacity to identify and combat tumor cells, providing patients with a safer alternative to conventional treatments.

Additionally, their gene therapy platform employs Adeno-Associated Virus (AAV) technology, which is aimed at addressing various cardiovascular conditions. These therapies represent significant advancements in treatment modalities, developed with the goal of improving patient outcomes. Theragene serves a diverse clientele across the United States and Asia, focusing on hospitals, oncology clinics, and cardiovascular treatment centers, thereby ensuring that their innovative therapies reach patients in need of effective treatment options. Theragene Pharmaceuticals generates revenue through strategic partnerships and collaborations aimed at developing and commercializing its therapeutic products.

The company engages in B2B transactions with healthcare providers, research institutions, and pharmaceutical companies, facilitating the delivery of its immunotherapy and gene therapy solutions. Revenue streams are established through licensing agreements and collaborative development deals, which allow clients to access Theragene's proprietary technologies. Specific pricing structures for the company’s flagship products are set in accordance with the nature of the partnership or agreement, reflecting the therapeutic value and the innovative nature of the treatments offered. These revenue mechanisms enable Theragene to sustain its development efforts while expanding its market reach in targeted therapeutic areas.

Theragene Pharmaceuticals is focusing on the development of new products in immunotherapy and gene therapy, with plans to expand its offerings to address additional cancer types and cardiovascular conditions by 2025. The company aims to penetrate new markets in Europe and Asia, targeting healthcare providers and research institutions by the end of 2025. The funding raised in the Seed round in December 2017 will be utilized to support these initiatives, facilitating further research and accelerated product development to enhance its therapeutic portfolio.